November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
November 2013 in “Journal of clinical & experimental dermatology research” Dutasteride can help treat hair loss in both men and women.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
July 2017 in “OPAL (Open@LaTrobe) (La Trobe University)” High-throughput LC-MS screening is effective for finding new autotaxin inhibitors for asthma treatment.
12 citations
,
March 2013 in “Gynecological Endocrinology” The study found a significant link between the renin-angiotensin system and insulin resistance in women with polycystic ovary syndrome.
1 citations
,
May 2001 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.
9 citations
,
August 2013 in “PLOS ONE” Genetic variants at 20p11 increase baldness risk in Chinese Han people.
44 citations
,
January 2023 in “New Phytologist” FER and TOR signaling help root hair growth in low temperature and low nitrate conditions.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
24 citations
,
January 2023 in “Cancer Research” AMPK activation may reduce melanoma risk in red-haired individuals.
36 citations
,
July 2007 in “Journal of Investigative Dermatology” Certain HLA class II alleles increase or decrease the risk of alopecia areata.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
February 2018 in “The Journal of Sexual Medicine” DA-9401 protects against hair loss, improves organ function, and prevents infertility caused by finasteride.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
1 citations
,
September 2023 in “Meditsinskiy sovet = Medical Council” Combining NB-UVB 311 nm therapy with standard treatment improves hair regrowth in children with alopecia areata and atopic dermatitis.
May 2025 in “Journal of Experimental Pharmacology” Allium ascalonicum L. extract may help improve insulin resistance.
February 2025 in “Biomolecules” RORA boosts autophagy in hair follicle stem cells, potentially aiding hair growth.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” Vemurafenib can cause scalp issues but can be managed without changing the dose.
1 citations
,
August 2024 in “GeroScience” 1 citations
,
August 2022 in “Frontiers in Medicine” ALRV5XR effectively promotes hair regrowth in both men and women through different mechanisms.
March 2021 in “Medico-Legal Update” The androgen receptor gene doesn't affect women with recurrent spontaneous abortions, but having a mutant genotype might protect against it.
August 2023 in “Journal of inflammation research” An elderly Chinese man lost all his hair after taking a new heart medication.
2 citations
,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
February 2009 in “RePub (Erasmus University Rotterdam)” Androgen receptor activity is influenced by hormones, co-factors, modifications, and mutations.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.